Dolutegravir
Class
Antiretroviral agents
Subclass
Integrase inhibitors
Substance name
Dolutegravir sodium
Brand names
Tivicay PD®
Common formulations
Tablet for oral suspension
Contained in
Abacavir / dolutegravir / lamivudine (Triumeq®)
Dolutegravir / lamivudine (Dovato®)
Dolutegravir / rilpivirine (Juluca®)
Indications for use
Off-label indications
Adults
Safety risks
Contraindications
A history of dolutegravir hypersensitivity
Warnings and precautions
Depression
Opportunistic infections
Reactivation of hepatitis
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B1
Breastfeeding
Do not use during breastfeeding.
Low excretion in breastmilk (5-25%).
Very low levels in breastfed infants (< 5%).
No overt adverse effects reported in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource